An Epidemiological Registry Study to Evaluate Clinical Practice Treatment in Patients With Bipolar Disorder

Completed

• Conditions: Bipolar Disorder

• Registration Number: NCT01455961
• Lead Sponsor: AstraZeneca

Brief Summary

The aim of this study is to describe the treatment pattern and patient characteristics in real life setting in patients with Bipolar disorder treated with Seroquel XR and/or Seroquel IR in Sweden.

Detailed Description

An epidemiological registry study to evaluate clinical practice treatment in patients with Bipolar Disorder treated with quetiapine XR and/or quetiapine IR

Study Timeline

• Study First Submitted: 2011-10-17
• Study First Submitted QC: 2011-10-19
• Study First Posted: 2011-10-20
• Study Start: 2011-11
• Primary Completion: 2012-04
• Study Completion: 2012-04
• Status Verified: 2014-08
• Last Update Submitted: 2014-08-20
• Last Update Posted: 2014-08-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 16000

Inclusion Criteria

• Patients with a diagnosis of BD.

Exclusion Criteria

• Patients with a diagnosis of any schizophrenia spectrum disorder after the diagnosis of bipolar disorder.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Description of detailed clinical treatment in terms of duration of treatment, doses, drug switches, and add-on therapy, in patients with BD and on treatment with quetiapine XR and/or quetiapine IR before, at and after the index date.	1st of January 2009 to 31st of December 2010.

Secondary Outcome Measures

Name	Time	Method
Description of co-morbidity, demographics, sick leave, early retirement and socioeconomic factors in patients with BD and on treatment with quetiapine XR and/or quetiapine IR before and at the index date.	1st of January 2009 to 31st of December 2010.
Description of the detailed clinical treatment in terms of duration of treatment, doses, drug switches, and add-on therapy, in patients with BD, including all drug treatment after the index date	1st of January 2009 to 31st of December 2010.
Description of co-morbidity, demographics, sick leave, early retirement and socioeconomic factors in patients with BD, including all drug treatment before and at the index date	1st of January 2009 to 31st of December 2010.